AU2017235608B2 - Novel alpha-1-microglobulin derived proteins and their use - Google Patents

Novel alpha-1-microglobulin derived proteins and their use Download PDF

Info

Publication number
AU2017235608B2
AU2017235608B2 AU2017235608A AU2017235608A AU2017235608B2 AU 2017235608 B2 AU2017235608 B2 AU 2017235608B2 AU 2017235608 A AU2017235608 A AU 2017235608A AU 2017235608 A AU2017235608 A AU 2017235608A AU 2017235608 B2 AU2017235608 B2 AU 2017235608B2
Authority
AU
Australia
Prior art keywords
glu
thr
gly
lys
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017235608A
Other languages
English (en)
Other versions
AU2017235608A1 (en
Inventor
Anneli Edström HÄGERWALL
Lena Wester ROSENLÖF
Bo Åkerström
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guard Therapeutics International AB
Original Assignee
Guard Therapeutics International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guard Therapeutics International AB filed Critical Guard Therapeutics International AB
Publication of AU2017235608A1 publication Critical patent/AU2017235608A1/en
Assigned to Guard Therapeutics International AB reassignment Guard Therapeutics International AB Amend patent request/document other than specification (104) Assignors: A1M Pharma AB.
Application granted granted Critical
Publication of AU2017235608B2 publication Critical patent/AU2017235608B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717Plasma globulins, lactoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
AU2017235608A 2016-03-18 2017-03-17 Novel alpha-1-microglobulin derived proteins and their use Active AU2017235608B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670158 2016-03-18
DKPA201670158 2016-03-18
PCT/EP2017/056436 WO2017158181A1 (en) 2016-03-18 2017-03-17 Novel alpha-1-microglobulin derived proteins and their use

Publications (2)

Publication Number Publication Date
AU2017235608A1 AU2017235608A1 (en) 2018-10-18
AU2017235608B2 true AU2017235608B2 (en) 2020-10-22

Family

ID=56080208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017235608A Active AU2017235608B2 (en) 2016-03-18 2017-03-17 Novel alpha-1-microglobulin derived proteins and their use

Country Status (15)

Country Link
US (1) US10981963B2 (enExample)
EP (1) EP3430032B1 (enExample)
JP (1) JP6976579B2 (enExample)
KR (1) KR102437662B1 (enExample)
CN (1) CN108779157B (enExample)
AU (1) AU2017235608B2 (enExample)
BR (1) BR112018068522A2 (enExample)
CA (1) CA3017836A1 (enExample)
EA (1) EA039776B1 (enExample)
ES (1) ES2896734T3 (enExample)
MX (1) MX2018011193A (enExample)
NZ (1) NZ746677A (enExample)
SG (1) SG11201807352XA (enExample)
WO (1) WO2017158181A1 (enExample)
ZA (1) ZA201805797B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511386A (zh) * 2017-11-03 2020-08-07 卫士医疗国际公司 α-1-微球蛋白用于保护骨髓细胞的用途
WO2024165674A1 (en) 2023-02-08 2024-08-15 Guard Therapeutics International AB Alpha-1-microglobulin derived peptide fragments and uses thereof
US12227343B2 (en) * 2023-03-17 2025-02-18 Blue Buffalo Enterpises, Inc. Retail ready opening feature for e-commerce carton

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006809A2 (en) * 2008-07-18 2010-01-21 Akerstroem Bo Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
WO2014037390A1 (en) * 2012-09-05 2014-03-13 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113851A1 (en) * 2012-01-31 2013-08-08 Technische Universitaet Muenchen Muteins of a1m lipocalin and method of production therefor
WO2014047490A1 (en) * 2012-09-21 2014-03-27 Beintoo, S.P.A. Interactive experience fully contained within an expandalble embedded unit
US10226570B2 (en) * 2017-03-10 2019-03-12 Seton Healthcare Family Apparatus and method for temporarily securing a movable accessory device relative to a movable patient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006809A2 (en) * 2008-07-18 2010-01-21 Akerstroem Bo Medical use of the radical scavenger and antioxidant alpha-1-microglobulin
WO2014037390A1 (en) * 2012-09-05 2014-03-13 A1M Pharma Ab Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases

Also Published As

Publication number Publication date
SG11201807352XA (en) 2018-09-27
ES2896734T3 (es) 2022-02-25
WO2017158181A1 (en) 2017-09-21
JP2019519466A (ja) 2019-07-11
NZ746677A (en) 2023-02-24
EP3430032A1 (en) 2019-01-23
CN108779157B (zh) 2022-12-30
US10981963B2 (en) 2021-04-20
BR112018068522A2 (pt) 2019-01-22
US20190161524A1 (en) 2019-05-30
EA201892085A1 (ru) 2019-02-28
KR102437662B1 (ko) 2022-08-29
EP3430032B1 (en) 2021-09-01
EA039776B1 (ru) 2022-03-11
CN108779157A (zh) 2018-11-09
ZA201805797B (en) 2022-03-30
CA3017836A1 (en) 2017-09-21
AU2017235608A1 (en) 2018-10-18
MX2018011193A (es) 2019-03-28
JP6976579B2 (ja) 2021-12-08
KR20180127411A (ko) 2018-11-28

Similar Documents

Publication Publication Date Title
CA2862516C (en) Compositions and methods of use for treating metabolic disorders
AU784845B2 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
KR100393508B1 (ko) 인간 인터루킨 4의 안타고니스트 또는 부분적 아고니스트로서의 신규hIL-4 변이단백질
US20220370560A1 (en) Ptd-smad7 therapeutics
EP2100968B1 (en) Method of producing recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo
US20120142613A1 (en) Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway
AU2017235608B2 (en) Novel alpha-1-microglobulin derived proteins and their use
CA2906775A1 (en) Bh4 stabilized peptides and uses thereof
AU2014233219B2 (en) Methods for treatment of nephrotic syndrome and related conditions
AU2003234066B2 (en) Muteins of placental growth factor type 1, preparation method and application thereof
WO2025172720A1 (en) Fragment of complement factor h related protein 5 which restores complement regulation
KR102077984B1 (ko) 피부 주름 예방 및 개선용 조성물
HK1130290B (en) Method of producing recombinant tat-hoxb4h protein for use as a stimulant of hematopoiesis in vivo

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: GUARD THERAPEUTICS INTERNATIONAL AB

Free format text: FORMER NAME(S): A1M PHARMA AB.

FGA Letters patent sealed or granted (standard patent)